Dietary modulation of the human colonic microbiota: updating the concept of prebiotics

Glenn R. Gibson1, Hollie M. Probert1, Jan Van Loo2*, Robert A. Rastall1 and Marcel B. Roberfroid3

1Food Microbial Sciences Unit, School of Food Biosciences, The University of Reading, Reading, UK
2Orafti, Aandorenstraat 1, B3300 Tienen, Belgium
3Université Catholique de Louvain, Brussels, Belgium

Prebiotics: non-digestible (by the host) food ingredients that have a beneficial effect through their selective metabolism in the intestinal tract. Key to this is the specificity of microbial changes. The present paper reviews the concept in terms of three criteria: (a) resistance to gastric acidity, hydrolysis by mammalian enzymes and gastrointestinal absorption; (b) fermentation by intestinal microflora; (c) selective stimulation of the growth and/or activity of intestinal bacteria associated with health and wellbeing. The conclusion is that prebiotics that currently fulfil these three criteria are fructo-oligosaccharides, galacto-oligosaccharides and lactulose, although promise does exist with several other dietary carbohydrates. Given the range of food vehicles that may be fortified by prebiotics, their ability to confer positive microflora changes and the health aspects that may accrue, it is important that robust technologies to assay functionality are used. This would include a molecular-based approach to determine flora changes. The future use of prebiotics may allow species-level changes in the microbiota, an extrapolation into genera other than the bifidobacteria and lactobacilli, and allow preferential use in disease-prone areas of the body.

Prebiotics: Criteria for prebiotic classification: Gut flora: Oligosaccharides

Introduction

A prebiotic was first defined as a ‘non-digestible food ingredient that beneficially affects the host by selectively stimulating the growth and/or activity of one or a limited number of bacteria in the colon, and thus improves host health’ (Gibson & Roberfroid, 1995). However, a prebiotic effect has been attributed to many food components, sometimes without due consideration to the criteria required. In particular, many food oligosaccharides and polysaccharides (including dietary fibre) have been claimed to have prebiotic activity, but not all dietary carbohydrates are prebiotics. There is, therefore, a need to establish clear criteria for classifying a food ingredient as a prebiotic. Such classification requires a scientific demonstration that the ingredient:

(1) resists gastric acidity, hydrolysis by mammalian enzymes and gastrointestinal absorption;
(2) is fermented by the intestinal microflora;
(3) stimulates selectively the growth and/or activity of intestinal bacteria associated with health and wellbeing.

As with functional foods or ingredients (Diplock et al. 1999), the final demonstration should be carried out in vivo, through appropriate nutritional feeding trials in the targeted species (i.e. man, livestock or companion animals). The methodologies used must be validated and supported by sound science.

Although each of these criteria is important, the third, concerning the selective stimulation of growth and/or activity of bacteria, is the most contentious and difficult to fulfil. Indeed, it requires anaerobic sampling followed by reliable and quantitative microbiological analysis of a wide variety of bacterial genera, for example, total aerobes and anaerobes, Bacteroides, Bifidobacterium, Clostridium, enterobacteria, Eubacterium, and Lactobacillus. Simply reporting fermentation in pure cultures of single microbial strains or an increase in a limited number of bacterial genera in complex mixtures of bacteria (for example, faecal slurries) either in vitro or in vivo cannot confirm a prebiotic effect. This is because it does not take bacterial interactions into account. Molecular-based microbiological methodologies have been...
developed and should be applied to prebiotic demonstrations (as discussed later; p. 261). Regarding the stimulation of bacterial activity, the patterns of production of organic acids, gases and enzymes have been used. However, these have not been validated as biomarkers of specific bacterial genera.

In light of these criteria and the aforementioned considerations, the aim of the present paper is to review and discuss methodologies to demonstrate scientifically a prebiotic effect as well as to evaluate evidence available for proving the prebiotic nature of candidate ingredients (hitherto these are all carbohydrates). The present paper also updates the initial definition of a prebiotic and reviews the status 8 years from its first introduction (Gibson & Roberfroid, 1995). The information in the present review is based upon literature searches last updated in July 2003.

Testing methodologies

It is apparent that if good-quality and biologically meaningful data are to be collected on different prebiotics, standardised testing methodologies are needed. We have suggested a scheme for the evaluation of a candidate prebiotic (Gibson et al. 1999). Such rigorous testing of candidate molecules is essential if we are to have confidence in any health claims made by manufacturers of functional foods. It is important also that the rationale behind the prebiotic effect is elucidated through mechanistic explanations of the effect. In this context, several genes specific for oligosaccharide metabolism have been identified in bifidobacteria to help explain the selective action of prebiotics that is clearly an integral part of the overall prebiotic effect (Schell et al. 2002).

Non-digestibility: testing prebiotic resistance to gastric acidity, hydrolysis by mammalian enzymes and gastrointestinal absorption

This first criterion must be fulfilled and can be demonstrated both in vitro and in vivo.

In vitro methods. In vitro demonstration includes determining resistance to acidic conditions (for example, those that occur in the stomach) and enzymic (saliva, pancreatic and small intestinal) hydrolysis (Oku et al. 1984; Ziesenitz & Siebert, 1987; Nilsson & Bjöck, 1988; Molis et al. 1996). After an appropriate incubation, hydrolysis products are assayed chemically or enzymically using standard methods (Dahlqvist & Nilsson, 1984).

In vivo models. Resistance to any endogenous digestive process can be shown by measuring the recovery in faeces of an oral dose given to germ-free rats or after antibiotic pre-treatment to suppress the intestinal flora (Nilsson et al. 1988). Other, more invasive methods involve intubation into the gastrointestinal system of living anaesthetised rats (Nilsson et al. 1988).

Models applicable to man involve either the direct recovery of non-digested molecules or an indirect assessment that neither glycaemia nor insulinaemia are increased significantly following oral administration. Direct approaches include either oral intubation to allow distal ileum fluid sampling (Molis et al. 1996) or the use of individuals who have been subjected to proctocolectomy, the so-called ileostomy patients (Bach Knudsen & Hessov, 1995; Ellegard et al. 1997). This model is widely accepted as a valuable alternative to study the small-intestinal excretion of nutrients (Langkilde et al. 1990; Cummings & Englyst, 1991). The intubation technique, with an unabsorbable marker, is used to quantitatively assess ileal flow (Phillips & Giller, 1973; Levitt & Bond, 1977).

Fermentation by intestinal microflora

In vitro methods. The most commonly used in vitro models to study anaerobic fermentation of carbohydrates by mixed bacterial populations, particularly faecal bacteria, are batch and continuous culture fermentation systems. Batch culture fermenters are inoculated with either pure culture(s) of selected species of bacteria or, preferably, with a faecal slurry and the carbohydrate to be studied.

Multi-chamber continuous culture systems have been developed to reproduce the physical, anatomical and nutritional characteristics of gastrointestinal regions (Macfarlane et al. 1998; Gmeiner et al. 2000). These models are useful for predicting both the extent and site of prebiotic fermentation.

In vivo methods. The in vivo fermentation of non-digestible carbohydrates can be studied in laboratory and companion animals, in livestock and in human subjects.

In laboratory animals, often rats, the prebiotic under investigation is added to food or drinking water but can be administered by gastric intubation. Animals are then anaesthetised and killed at pre-determined time points. Faecal samples, and the contents of the gastrointestinal segments, are collected for analysis. One interesting model by which to study carbohydrate fermentation in experimental animals is the heteroxenic rat harbouring a human faecal flora.

To study the fermentation of dietary carbohydrates in human subjects, two major approaches are used. The first is indirect, in which exhaled air is collected at regular time intervals to measure the concentration of gases, essentially $H_2$, in volunteers previously given a single oral dose of the carbohydrate (Christl et al. 1992). The other approach consists of collecting faeces after oral feeding and measuring the recovery of the test carbohydrate.

Selective stimulation of growth and/or activity of intestinal bacteria

As the field of prebiotics has developed, so has the methodology for investigating functionality; in particular, flora compositional changes as a response to the selective fermentation. Much of the early (and some of the current) literature describes studies performed on pure cultures. Typically, this involves the selection of a range of strains of *Bifidobacterium* spp., *Lactobacillus* spp. and other bacteria such as *Bacteroides* spp., *Clostridium* spp., *Eubacterium* spp. and *Escherichia coli*. The number of strains tested varies with different reports. The problem with this
approach is, of course, that the strains selected cannot truly be considered as representative of the colonic microbiota. This is further compounded in some studies as authors have used a wide range of bifidobacteria and lactobacilli but only one or two strains of the ‘undesirable’ species. Such studies cannot establish that the test carbohydrate is metabolised selectively and should be used for initial screening purposes only.

A more meaningful in vitro method for studying prebiotic oligosaccharides is the use of faecal inocula, which ensures that a representative range of bacterial species is exposed to the test material. Study of the changes in populations of selected genera or species can then establish whether the fermentation is selective. The use of faeces probably gives an accurate representation of events in the distal colon. However, more proximal areas will have a more saccharolytic nature, and both the composition and activities of the microbiota indigenous to the colon are variable, dependent upon the region being sampled. This has been confirmed through studies on sudden-death victims, where the colon contents were sampled shortly following death (Macfarlane et al. 1992, 1998). The complex gut models, which replicate different anatomical areas, attempt to overcome this and should be used in concert with human trials.

**Culture on selective media.** One major problem with the use of faecal inocula is identification of the genera and species present. Traditionally, this has been accomplished by culturing on a range of purportedly selective agars followed by morphological and biochemical tests designed to confirm culture identities (van Houte & Gibbons, 1966; Finegold et al. 1974). This approach is adequate to establish that a prebiotic selectively enriches defined ‘desirable’ organisms and depletes ‘undesirable’ organisms but does not give a true picture of the population changes occurring. This is unavoidable when using a selective culture, as it is estimated that only about 50 % of the diversity present in the human colon has yet been characterised (Suau et al. 1999).

A much more reliable approach involves the use of molecular methods of bacteria identification. These have advantages over culture-based technologies in that they have improved reliability and can encompass the full flora diversity. Examples of the molecular procedures are given below.

**Fluorescence in situ hybridisation.** Modern techniques are now available whereby bacterial enumeration can be carried out in a quick, culture-independent and reliable manner such as fluorescence in situ hybridisation (FISH). This technique involves the use of group-specific (and in some cases species-specific) oligonucleotide probes that target discrete discriminatory regions of the rRNA molecule. By targeting highly conserved areas of the rRNA, specific groups of bacteria can be distinguished from others in a mixed culture.

A host of phylogenetic probes are currently available for the enumeration of faecal bacteria, whilst more are being designed and validated. Groups targeted include Bacteroides spp. (Manz et al. 1996), Bifidobacterium spp. (Langendijk et al. 1995) and Lactobacillus and Enterococcus spp. (Harmsen et al. 1999), Eubacterium (Franks et al. 1998), and Clostridium (Tuohy et al. 2001).

As well as being a relatively quick technique, this method removes the ambiguity that is a prominent feature of traditional selective agars. Additionally, FISH provides a means through which hitherto unculturable bacterial species of the gut may be investigated, since this is a culture-independent technique and therefore does not require prior, often anaerobic, growth of an organism upon laboratory media ( Liesack & Stackebrandt, 1992).

**Polymerase chain reaction.** Due to the ambiguity inherent in using purportedly selective agars, only tenuous identifications of bacteria can be made using this methodology. Bacterial ribosomes offer the means by which identifications can be made at a molecular level. The genes that code for the 16S subunits of the bacterial ribosomes are comprised of both conserved and variable regions, and sequencing of the 16S rRNA gene enables bacterial identifications to be made. By using a process known as PCR, segments of this gene can be amplified to a level whereby their sequence can be determined (Steffan & Atlas, 1991).

**Direct community analysis.** Characterisation of both the culturable and non-culturable components of a microbial mixture may be achieved via direct community analysis. This process characterises the 16S rRNA diversity of the sample of interest. The total bacterial DNA is extracted from the sample and partial 16S rDNA genes are amplified (using universal primers) via PCR (Suau et al. 1999). The purified amplification products are subsequently cloned into E. coli, and clones containing the 16S rDNA inserts are sequenced and identified by comparison with database 16S rDNA sequences.

**Denaturing and temperature-gradient gel electrophoresis.** Another method to evaluate the genetic diversity of the intestinal microflora is denaturing gradient gel electrophoresis or temperature-gradient gel electrophoresis. These approaches separate amplified DNA fragments of the same size based on the extent of the sequence divergence between different PCR products (Muyzer & Smalla, 1998). A whole community PCR is carried out and partial 16S rDNA sequences are amplified from the different bacterial species present. Separation occurs due to the decreased electrophoretic mobility of the partially melted, double-stranded DNA molecule in polyacrylamide gels containing either a temperature or chemical denaturant gradient (Muyzer & Smalla, 1998). Identification can be carried out either by excising fragments from the gel and sequencing them, or by comparing their motility with that of known control sequences. As with FISH, both culturable and unculturable populations can be characterised and this relatively rapid technique also offers the potential of monitoring gut flora over time (Zoetendal et al. 1998). Table 1 summarises the principal techniques used for evaluating bacterial populations in faeces, along with some of their advantages and disadvantages.
Flow cytometry. Flow cytometry can be used to quantify bacteria using the FISH procedure. However, in the hands of the authors of the present review it has been problematic for assaying complex communities such as mixed faecal culture. This is because a great deal of background ‘noise’ exists. However, the throughput currently seen for pure or co-culture studies may eventually be realised for complex gut communities through further refinement of the flow cytometry techniques and improved discrimination as a result.

Review of candidate prebiotics

For each candidate, a brief introduction will give a description of the chemistry and manufacturing process followed by a review of the data available to fulfill the three criteria for prebiotic classification, which are:

1. resistance to gastric acidity, hydrolysis by mammalian enzymes and gastrointestinal absorption;
2. fermentation by intestinal microflora;
3. selective stimulation of the growth and/or activity of intestinal bacteria associated with health and wellbeing.

Inulin

Chemistry, nomenclature and manufacture of inulin. From a chemical point of view, the linear chain of inulin is either an α-D-glucopyranosyl-[β-D-fructofuranosyl]n-1β-D-fructofuranoside (GpF)n or a β-D-fructopyranosyl-[β-D-fructofuranosyl]n-1β-D-fructofuranoside. The fructosyl–glucose linkage is always β(2→1) as in sucrose, but the fructosyl–fructose linkages are β(1→2).

Chicory inulin is composed of a mixture of oligomers and polymers in which the degree of polymerisation (DP) varies from two to approximately sixty units with an average DP (DPav) of twelve. About 10% of the fructan chains in native chicory inulin have a DP ranging between two (F2) and five (GF5). The partial enzymic hydrolysis of inulin using an endo-inulinase (EC 3.2.1.7) produces oligofructose, which is a mixture of both GpF and β-D-fructopyranosyl-[β-D-fructofuranosyl]n-1β-D-fructofuranoside molecules, in which the DP varies from two to seven with a DPav of four. Oligofructose can be obtained by enzymic synthesis (transfructosylation) using the fungal enzyme β-fructosidase (EC 3.2.1.7) from Aspergillus niger. In such a synthetic compound, the DP varies from two to four with a DPav of 3.6, and all oligomers are of the GpFn type. By applying specific separation technologies, the food industry also produces a long-chain inulin known as high-polymer inulin (DP of ten to sixty) with a DPav of twenty-five. Finally, by mixing oligofructose and long-chain inulin, specific products known as Synergy® (Orafti NV, Tienen, Belgium) have been developed. The different industrial products vary in DPav maximum DP, and DP distribution, and they have varying properties (Franck, 2002).

Inulin is a generic term that covers all β(1→2) linear molecules. In any circumstances that justify the identification of the oligomers v. polymers, the terms oligofructose and/or inulin can be used, respectively. Even though the inulin hydrolysate and the synthetic compound have a slightly different DPav (four and 3.6, respectively), the term oligofructose can be used to identify both. Indeed, oligofructose and fructo-oligosaccharides are considered to be synonymous names for the mixture of small inulin oligomers with maximum DP of less than ten (Quemener, 1994; Roberfroid et al. 1998; Coussement, 1999; Roberfroid, 2002).

Criterion 1: resistance to gastric acidity, hydrolysis by mammalian enzymes and gastrointestinal absorption. The resistance of inulin to digestive processes has been studied extensively by applying all the methods (both in vitro and in vivo) described earlier (p. 260) in the section regarding testing methodologies. Inulin is a non-digestible oligosaccharide that, for nutritional labelling, is classified as dietary fibre.

Criterion 2 and 3: fermentation by intestinal microflora and selective stimulation of the growth and/or activity of intestinal bacteria associated with health and wellbeing. In vitro data supporting the selective stimulation of bacterial growth by inulin has been generated in numerous studies that are summarised in Table 2. This has been carried out in defined pure culture fermentation and by using a mixed faecal inocula in both batch and continuous culture (Wang & Gibson, 1993; Gibson & Wang, 1994a; Roberfroid et al. 1998).

<table>
<thead>
<tr>
<th>Method</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selective culturing and biochemical characteristics</td>
<td>Straightforward, relatively inexpensive, a large number of replicates can be carried out</td>
<td>Operator subjectivity, applicable only to culturable bacteria, selectivity of media is ambiguous, metabolic plasticity of organisms may introduce error</td>
</tr>
<tr>
<td>Fluorescence in situ hybridisation</td>
<td>Can be used on unculturable as well as culturable bacteria, highly specific</td>
<td>Can probe only for known bacteria, more time-consuming than culture procedures</td>
</tr>
<tr>
<td>PCR</td>
<td>High fidelity, reliable, allows placement of previously unidentified bacteria, can be used for unculturable bacteria</td>
<td>Expensive, time-consuming. Some bias in the PCR process</td>
</tr>
<tr>
<td>Direct community analysis</td>
<td>Culture independent, the diversity of entire samples can be elucidated</td>
<td>Some loss of bacterial diversity due to the bias introduced by PCR</td>
</tr>
<tr>
<td>Denaturing and temperature-gradient gel electrophoresis</td>
<td>Rapid, can be used for both culturable and unculturable bacteria</td>
<td>Qualitative rather than quantitative, bias introduced by the PCR process may lead to a loss of diversity</td>
</tr>
</tbody>
</table>

Table 1. Principal methodologies employed to enumerate colonic bacteria
As well as in vitro work, in vivo studies have been carried out using animal models, for example with germ-free rats associated with a human faecal flora. A bifidogenic effect was observed in rats fed oligofructose, whilst lactobacilli were mostly increased in rats fed oligofructose alone or a mixture of oligofructose and inulin. This same mixture led to smaller numbers of clostridia, whilst short-chain fructo-oligosaccharides and/or inulin increased the relative proportion of butyrate (Levrat et al. 1991; Campbell et al. 1997; Kleessen et al. 2001; Poulsen et al. 2002).

Human trials with oligofructose and inulin include those with a controlled diet, and cross-over feeding trials, although the dose, substrate, duration and volunteers vary (Mitsuoka et al. 1987; Gibson et al. 1995; Buddington et al. 1996; Kleessen et al. 1997b; Bouhnik et al. 1999; Menne et al. 2000; Tuohy et al. 2001) (Table 3). The efficacy of inulin has been evaluated with a view to its administration to formula-fed infants (Coppa et al. 2002). Moro et al. (2002) observed an increase in bifidobacteria and lactobacilli in infants who received formula milk supplemented with a mixture of inulin and galacto-oligosaccharides, indicating its prospects in infant nutrition.

In these in vivo trials, there were large variations between the subjects in their microflora compositions and response to the substrates (Hidaka, 1986; Williams et al. 1994), particularly between Western and Eastern subjects (Buddington et al. 1996). Another general observation was the decrease in bifidobacteria once administration of the oligofructose and inulin ceased (Bouhnik, 1994; Gibson et al. 1995; Buddington et al. 1996).

Conclusion. Together, the evidence available today both from in vitro and in vivo experiments supports the classification of inulin and oligofructose as prebiotic, since they fulfil all three criteria.

### Table 2. Studies carried out demonstrating the in vitro selectivity of inulin in pure culture, mixed batch culture and mixed continuous culture fermentation

<table>
<thead>
<tr>
<th>Study</th>
<th>Observations</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Examining the growth of bifidobacteria on different types of oligofructose in pure culture. Eight species tested as well as species of Clostridium, Bacteroides, Enterococci and Escherichia coli</td>
<td>Linear oligofructose had more of a bifidogenic effect than greater molecular-mass molecules and branched-chain varieties. <em>Bifidobacterium</em> species showed a preference for fructans compared with glucose</td>
<td>Gibson &amp; Wang (1994b)</td>
</tr>
<tr>
<td>Species of Bifidobacterium (longum, breve, pseudocatenulatum, adolescentis) were tested in pure culture for their ability to ferment oligofructose</td>
<td><em>B. adolescentis</em> was seen to grow best and was able to metabolise both short- and long-chain oligofructose</td>
<td>Marx et al. (2000)</td>
</tr>
<tr>
<td>The ability of Bifidobacterium and Lactobacillus to grow on MRS agar containing oligofructose was investigated</td>
<td>Seven out of eight bifidobacteria and twelve out of sixteen lactobacilli were able to grow on agar containing oligofructose</td>
<td>Kaplan &amp; Hutkins (2000)</td>
</tr>
<tr>
<td>Batch culture using faecal inocula to study fermentation of inulin, oligofructose, starch, polydextrose, fructose and pectin</td>
<td><em>Bifidobacteria</em> most increased with oligofructose and inulin whilst populations of <em>E. coli</em> and <em>Clostridium</em> were maintained at relatively low levels</td>
<td>Wang &amp; Gibson (1993)</td>
</tr>
<tr>
<td>Batch culture using faecal inocula to study fermentation of oligofructose, branched fructan, levans, maltodextrin</td>
<td>Fluorescence <em>in situ</em> hybridisation revealed that branched fructan had the best prebiotic effect, followed by oligofructose</td>
<td>Probert &amp; Gibson (2002)</td>
</tr>
<tr>
<td>Continuous culture fermentation to study fermentation of oligofructose</td>
<td>Selective culturing showed <em>Bifidobacterium</em> and, to a lesser extent, <em>Lactobacillus</em>, preferred oligofructose to inulin and sucrose. <em>Bacteroides</em> could not grow on oligofructose</td>
<td>Gibson &amp; Wang (1994b)</td>
</tr>
</tbody>
</table>

### Transgalacto-oligosaccharides

Chemistry and manufacture of transgalacto-oligosaccharides. Transgalacto-oligosaccharides (TOS) are a mixture of oligosaccharides derived from lactose by enzymic transglycosylation (Crittenden, 1996). The product mixtures depend upon the enzymes used and the reaction conditions. They generally consist of oligosaccharides from tri- to pentasaccharide with β(1→6), β(1→3) and β(1→4) linkages (Matsumoto et al. 1993). This diversity must be borne in mind when considering some of the early studies on these materials; different studies have almost certainly used oligosaccharide mixtures with different compositions. It is thus essential that the exact composition of the mixture be given in reports of studies.

Criterion 1: resistance to gastric acidity, hydrolysis by mammalian enzymes and gastrointestinal absorption. The data on non-digestibility do not fully match the criteria. However, there are suggestions that TOS do reach the colon intact (Tomomatsu, 1994).

Criterion 2 and 3: fermentation by intestinal microflora and selective stimulation of the growth and/or activity of intestinal bacteria associated with health and wellbeing. An early study by Minami et al. (1983) examined the fermentation of ‘isogalactobiose’ of unknown linkage and found that one strain of each of *Bifidobacterium infants*, *B. longum*, *B. adolescentis* and *Lactobacillus acidophilus* metabolised it, whilst one strain each of *Enterococcus fecalis* and *E. coli* could not. A more extensive study found that many strains of enteric bacteria could not metabolise the isogalactobiose. Tanaka et al. (1983) also studied enzymically synthesised TOS in a pure culture study. These authors found that all of the bifidobacteria tested, all of the bacteroides, most lactobacilli and enterobacteria and some streptococci...
metabolised the TOS, with bifidobacteria displaying the most vigorous growth. However, the available in vitro data do not fully demonstrate a selective stimulation of bacterial growth.

In a study by Rowland & Tanaka (1993), gnotobiotic rats inoculated with human faecal flora were fed a TOS-containing diet before being killed. Caecal contents analysed on selective agars revealed significant increases in bifidobacteria and lactobacilli, and a significant decrease in enterobacteria. Bifidobacteria decreased as a percentage of total anaerobes, suggesting growth of other anaerobic bacteria not enumerated by the selective agars. These authors found significant decreases in nitrite reductase and β-glucuronidase.

This was followed by an in vivo volunteer feeding study that showed significant increases in bifidobacteria. This study, however, fed subjects for only 1 week per dose and there was no reported washout period between treatments. More recently, Bouhnik et al. (1997) found a significant increase in faecal bifidobacteria whilst populations of enterobacteria did not change following TOS feeding. Ito et al. (1990) fed TOS to male volunteers and found significant increases in bifidobacteria and lactobacilli. Similarly, Ito et al. (1993) found a significant increase in bifidobacteria and lactobacilli, and significant decreases in Bacteroides and Candida. They found significant decreases in ammonium, cresol, indole, propionate, valerate, isobutyrate and isovalerate, but no change in acetate or butyrate.

Infant formula milk supplemented with a mixture of oligosaccharides (90 % galacto-oligosaccharide and 10 % inulin) has been shown to increase faecal bifidobacteria in both preterm and term infants (Dubey & Mistry, 1996; Knol, 2001; Rivero-Urgell & Santamaria-Orleans, 2001; Boehm et al. 2002; Moro et al. 2002; Vandenplas, 2002).

### Table 3. Studies carried out demonstrating the in vivo selective stimulation of bacterial growth by inulin and oligofructose in human feeding trials

<table>
<thead>
<tr>
<th>Study</th>
<th>Observations</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Twenty-three subjects fed 8 g oligofructose/d for 2 weeks</td>
<td>Increase in faecal bifidobacteria by about ten times and decrease in stool pH</td>
<td>Mitsuoka et al. (1987)</td>
</tr>
<tr>
<td>Eight subjects on a controlled diet were fed 15 g oligofructose/d for 15 d, then four of these subjects were fed 15 g inulin/d for 15 d</td>
<td>Selective agars showed that oligofructose increased faecal bifidobacteria and decreased Bacteroides. clostridia and fusobacteria. Inulin increased bifidobacteria and decreased Gram-positive cocci</td>
<td>Gibson et al. (1995)</td>
</tr>
<tr>
<td>Twenty subjects were fed 12.5 g oligofructose/d for 12 d</td>
<td>Significant increase in bifidobacteria by about ten times was demonstrated on selective agars</td>
<td>Bouhnik et al. (1996)</td>
</tr>
<tr>
<td>Twelve young subjects were administered 4 g oligofructose/d for a period of 2 weeks</td>
<td>The bifidobacteria increased by 0-8 log unit</td>
<td>Buddington et al. (1996)</td>
</tr>
<tr>
<td>Ten female elderly subjects were given 20 and 40 g inulin/d</td>
<td>On selective agars a tenfold increase in bifidobacteria and significant decreases in Bacteroides were observed</td>
<td>Kleessen et al. (1997b)</td>
</tr>
<tr>
<td>Oligofructose (2.5, 10, and 20 g/d) fed for 7 d in a trial involving forty subjects</td>
<td>Selective agars showed that bifidobacteria were most increased by 10 and 20 g doses of oligofructose compared with 2.5 g and that the optimum dose of oligofructose was found to be 10 g/d</td>
<td>Bouhnik et al. (1999)</td>
</tr>
<tr>
<td>Chicory inulin hydrosylate (8 g/d) fed to eight subjects in a controlled feeding study</td>
<td>Selective agars showed an increase in faecal bifidobacteria</td>
<td>Menne et al. (2000)</td>
</tr>
<tr>
<td>Controlled feeding study where up to 34 g inulin/d were given to eight subjects for a period of 2 months</td>
<td>FISH revealed an increase in bifidobacteria from 9-8 to 11.0 log_{10} cells/g dry faeces. The effect lasted for the whole 2 months that the volunteers received the prebiotic</td>
<td>Kruse et al. (1999)</td>
</tr>
<tr>
<td>Oligofructose (5 g/d) was given to eight young and healthy volunteers for a period of 3 weeks</td>
<td>By means of selective agars, an increase in faecal bifidobacteria was observed</td>
<td>Rao (2001)</td>
</tr>
<tr>
<td>Biscuits containing oligofructose and partially hydrolysed guar gum and placebo biscuits were fed to thirty-one subjects for 21 d cross-over periods</td>
<td>FISH revealed an increase in faecal bifidobacteria</td>
<td>Tuohy et al. (2001)</td>
</tr>
<tr>
<td>Nineteen elderly patients fed 8 g oligofructose/d for 3 weeks</td>
<td>Increase in faecal bifidobacteria of approximately 2.8 log cfu/g of faeces</td>
<td>Guigoz et al. (2002)</td>
</tr>
<tr>
<td>Fourteen adult volunteers were given 9 g long-chain inulin/d for a period of 2 weeks</td>
<td>Quantification of all bacteria, bifidobacteria, the Erec group, bacteroides, and Eubacterium were counted with FISH probes. A significant increase in bifidobacteria and a significant decrease in the Erec group was observed</td>
<td>Harmsen et al. (2002)</td>
</tr>
</tbody>
</table>

FISH, fluorescence in situ hybridisation; Erec, Eubacterium rectale – Clostridium coccoides.
The prebiotic concept

**Conclusion.** Even though the first criterion for prebiotic classification is not totally fulfilled, TOS can be classified as prebiotic because of significant data from human studies.

**Lactulose**

Chemistry and manufacture of lactulose. Lactulose is manufactured by the isomerisation of lactose to generate the disaccharide galactosyl β-(1→4)fructose. It has found widespread application in the medical world as a laxative (Tamura, 1983).

Criterion 1: resistance to gastric acidity, hydrolysis by mammalian enzymes and gastrointestinal absorption. Investigations of the enzymic degradation of lactulose have found that human and calf intestinal β-galactosidases did not degrade lactulose (Gibson & Angus, 2000).

Criteria 2 and 3: fermentation by intestinal microflora and selective stimulation of the growth and/or activity of intestinal bacteria associated with health and wellbeing. One of the earliest studies on lactulose fermentation was that conducted by Sahota et al. (1982), who used thirty-seven species of bacteria in pure culture. They found that Bacteroides oralis, Bacteroides vulgatus, Bifidobacterium bifidum, Clostridium perfringens, L. casei sub. casei and four other strains of Lactobacillus spp. fermented lactulose. The in vitro data presently available do not demonstrate a selective stimulation of bacterial growth.

Tomoda et al. (1991) fed yoghurt made with lactulose to healthy volunteers. Faecal samples were analysed on ‘selective’ agars. These authors found a significant increase in bifidobacteria but no total anaerobic count was performed and no other bacteria were enumerated, providing no evidence of selective stimulation of growth.

A more microbiologically rigorous study was subsequently performed by Terada et al. (1993). Faecal samples were again analysed on agars as well as for enzymes and putrefactive products. Selective and significant increases in bifidobacteria and decreases in C. perfringens, streptococci, lactobacilli and lactobacilli were found.

A study by Ballongue et al. (1997) provided more evidence for a prebiotic effect for lactulose. In a parallel-group, randomised, double-blind, placebo-controlled trial, significant increases in Bifidobacterium, Lactobacillus and Streptococcus were found concomitant with significant decreases in Bacteroides, Clostridium, coliforms and Eubacterium. Concentrations of acetate and lactate were increased, whilst concentrations of butyrate, propionate and valerate decreased. All of the enzyme activities measured were lowered significantly (25–45 %). A recent study by Tuohy et al. (2002) has demonstrated, using FISH, that a statistically significant and selective increase in bifidobacteria occurred, following the feeding of lactulose.

**Isomalto-oligosaccharides**

Chemistry and manufacture of isomalto-oligosaccharides. Isomalto-oligosaccharides (IMO) are manufactured from starch, which is hydrolysed by the combined action of α-amylase and pullulanase, and the resultant maltoligosaccharides are acted upon by α-glucosidase (Kohmoto et al. 1988, 1991). α-Glucosidase catalyses a transfer reaction converting the α(1→4)-linked malto-oligosaccharides into α(1→6)-linked IMO. Commercial IMO consist of a mixture of oligosaccharides of differing molecular mass.

Criterion 1: resistance to gastric acidity, hydrolysis by mammalian enzymes and gastrointestinal absorption. Studies carried out by Kaneko et al. (1995) using rats demonstrated that IMO was digested slowly in the jejunum and that components with a higher DP were less digestible and that the hydrogenated derivative of IMO was non-digestible. As such, it enters the colon in variable amounts. No human data are available and it cannot be concluded that IMO are non-digestible or only partly so.

Criterion 2 and 3: fermentation by intestinal microflora and selective stimulation of the growth and/or activity of intestinal bacteria associated with health and wellbeing. The fermentation properties of IMO have been tested by a combination of pure culture studies and human volunteer trials.

Kohmoto et al. (1988) conducted a pure culture study in which they tested isomaltose, isomaltotriose, panose, and the commercial product Isomalto-9000 (Hyashibara Co. Ltd, Okayama, Japan). They found that B. adolescentis, B. longum, B. breve, and B. infantis (not B. bifidum) metabolised the test sugars. IMO were also metabolised by Bacteroides, Enterococcus faecalis and C. ramosus but not by a range of other enteric bacteria. At present, there appears to be no continuous culture fermentation work with IMO. The available in vitro data do not demonstrate a selective stimulation of bacterial growth. In vivo, the same authors carried out a volunteer trial that involved feeding IMO. Bacterial populations were determined by culture on selective agars. Significant increases in bifidobacteria were found.

The dose–response of IMO has been investigated by Kohmoto et al. (1991) in a volunteer trial involving feeding different doses. This study found a significant increase in bifidobacteria as determined by culture on agars that were only purportedly selective.

Because commercial IMO products contain a mixture of oligosaccharides, the influence of DP on fermentation, in vivo, has been studied by Kaneko et al. (1994). However, since these authors determined the counts of only bifidobacteria and the total microflora and no other bacterial group, the data do not fit the criteria for prebiotic effect.

**Conclusion.** Some of the evidence for prebiotic status for IMO appears to be promising but still not sufficient. In conclusion, IMO cannot, presently, be classified as prebiotics.
Lactosucrose

Chemistry and manufacture of lactosucrose. Lactosucrose is produced from a mixture of lactose and sucrose using the enzyme β-fructofuranosidase (Playne & Crittenden, 1996). The fructosyl residue is transferred from sucrose to the C-1 position of the glucose moiety in the lactose, producing a non-reducing oligosaccharide (Hara et al. 1994).

Criterion 1: resistance to gastric acidity, hydrolysis by mammalian enzymes and gastrointestinal absorption. There appears to be no data on this.

Criteria 2 and 3: fermentation by intestinal microflora and selective stimulation of the growth and/or activity of intestinal bacteria associated with health and wellbeing. The properties of lactosucrose have been studied by Kumemura et al. (1992) in chronically constipated patients. Faecal bacteria were enumerated on agars, although the follow-up characterisation procedures are not clear. These authors found a significant increase in bifidobacteria and a significant decrease in clostridia.

Ohkusa et al. (1995) carried out a volunteer study involving feeding a normal diet supplemented with lactosucrose. Faecal samples were collected and plated onto agars. A significant increase in bifidobacteria compared with pre-trial values was seen, together with a significant decrease in bacteroides compared with samples 1 week after termination.

Conclusion. The evidence for the prebiotic status of lactosucrose is still not sufficient. In conclusion, lactosucrose cannot, presently, be classified as prebiotic.

Xylo-oligosaccharides

Chemistry and manufacture of xylo-oligosaccharides. Xylo-oligosaccharides (XOS) are manufactured by the enzymic hydrolysis of xylan from maize cobs (Zea mays). The commercial products are predominantly composed of the disaccharide xylobiose with small amounts of higher oligosaccharides (Yamada, 1993).

Criterion 1: resistance to gastric acidity, hydrolysis by mammalian enzymes and gastrointestinal absorption. The parent molecule, xylan, is recognised as a dietary fibre, indicating that oligosaccharide versions may reach the colon intact. No data were found to support this assumption, however.

Criteria 2 and 3: fermentation by intestinal microflora and selective stimulation of the growth and/or activity of intestinal bacteria associated with health and wellbeing. The most informative studies on XOS are those carried out by Okazaki et al. (1990). These authors carried out an initial pure culture study involving a wide range of bacteria. This indicated that XOS were metabolised by the majority of bifidobacteria and lactobacilli tested but by few other bacteria, notable exceptions being Bacteroides and C. butyricum. A recent pure culture study by Jaskari et al. (1998) has shown that XOS from oat-spelt xylan was metabolised by bifidobacteria but also by bacteroides, C. difficile and E. coli. Lactobacilli did not metabolise the XOS. Although this study appears to show a lack of selectivity in the fermentation of XOS in contradiction to the studies reported on earlier, studies relying on pure cultures do not represent the situation in the colon. Crittenden & Playne (2002) suggested that bifidobacteria were able to utilise XOS but not xylan.

The in vitro data presently available do not demonstrate a selective stimulation of bacterial growth. A study in rats was carried out by Campbell et al. (1997). The authors examined faecal and caecal bacteria. Although only bifidobacteria, lactobacilli, total anaerobes and total aerobes were determined, significant increases in bifidobacteria occurred.

A volunteer trial involving feeding XOS to healthy men has been carried out (Okazaki et al. 1990). Bacteria were counted on agars and samples were analysed for SCFA. Significant increases were found in bifidobacteria and Megaspheara. There was also a significant increase in the concentration of organic acids in the faeces.

Conclusion. The evidence for the prebiotic status of XOS is still not sufficient.

In conclusion, therefore, XOS cannot, presently, be classified as prebiotic.

Soyabean oligosaccharides

Chemistry and manufacture of soyabean oligosaccharides. Soyabean oligosaccharides are α-galactosyl sucrose derivatives (raffinose, stachyose). They are isolated from soya beans and concentrated to form the commercial product (Crittenden, 1996).

Criterion 1: resistance to gastric acidity, hydrolysis by mammalian enzymes and gastrointestinal absorption. Raffinose and stachyose have been suggested to reach the colon after feeding to human subjects (Öku, 1994).

Criteria 2 and 3: fermentation by intestinal microflora and selective stimulation of the growth and/or activity of intestinal bacteria associated with health and wellbeing. The fermentation properties of these oligosaccharides have been studied either as mixtures of oligosaccharides or as individual components. In an early study, Minami et al. (1983) studied the fermentation of raffinose in pure cultures and found it to be metabolised by bifidobacteria and a range of enteric organisms whereas L. acidophilus, Enterococcus faecalis and E. coli could not. Hayakawa et al. (1990) compared pure raffinose and stachyose with refined soyabean oligosaccharides. In a pure culture study, bifidobacteria (with the exception of B. bifidum) and lactobacilli (with the exception of L. casei) metabolised the test sugars, whilst a range of other enteric bacteria did not metabolise them or did so poorly. A pure culture study by Jaskari et al. (1998) found that L. acidophilus, B. infantis, B. bifidum, B. longum, Bacteroides thetaiotomicron, and Bacteroides fragilis grew well on raffinose; E. coli grew poorly, whilst C. difficile did not grow.

The in vitro data presently available do not demonstrate a selective stimulation of bacterial growth.
A volunteer trial (Hayakawa et al. 1990) in healthy male adults found a significant increase in bifidobacteria with no change in putrefactive compounds.

Conclusion. The evidence for the prebiotic status of soya-bean-oligosaccharides is still not sufficient. In conclusion, and mostly because of the unreliable microbial methods, soya-bean oligosaccharides cannot, presently, be classified as prebiotic.

Gluco-oligosaccharides

Chemistry and manufacture of gluco-oligosaccharides. Gluco-oligosaccharides are synthesised by the action of the enzyme dextran sucrase (EC 2.4.1.5) on sucrose in the presence of maltose. The resulting oligosaccharides contain α(1→2) linkages such as the following tetrasaccharide:

\[ \text{glucosyl}(1\rightarrow2)\text{glucosyl}(1\rightarrow6)\text{glucosyl}(1\rightarrow4)\text{glucose}. \]

Gluco-oligosaccharides can be produced via fermentation using Leuconostoc mesenteroides.

Criterion 1: resistance to gastric acidity, hydrolysis by mammalian enzymes and gastrointestinal absorption. These oligosaccharides were not digested in a germ-free rat model system (Valette et al. 1993).

Criteria 2 and 3: fermentation by intestinal microflora and selective stimulation of the growth and/or activity of intestinal bacteria associated with health and wellbeing. Branched-chain oligomers produced using Leuconostoc mesenteroides B-742 have been shown to be utilised readily by bifidobacteria and lactobacilli in a pure culture study by Chung & Day (2002) but not by Salmonella spp. or E. coli.

The fermentation properties of these oligosaccharides have been studied by Djouzi et al. (1995), who carried out a pure culture study and found that gluco-oligosaccharides were utilised by B. breve, B. pseudocatenulatum and B. longum but not by B. bifidum. They were utilised also by Bacteroides spp. and Clostridium spp. but not by lactobacilli. They then carried out artificial mixed culture studies in anaerobic culture vessels using B. thetaiotomicron, B. breve and C. butyricum. Gluco-oligosaccharides were then fed to germ-free rats inoculated with the three cultures used in vitro (Djouzi et al. 1995). In this model, the gluco-oligosaccharides had no effect on bacterial populations.

Conclusion. The evidence for the prebiotic status of gluco-oligosaccharides is still not sufficient. In conclusion, gluco-oligosaccharide cannot, presently, be classified as prebiotics.

Miscellaneous carbohydrates

The prebiotic potential of several other compounds has been investigated. However, evidence pointing towards any prebiotic effect is too sparse to justify a detailed review or a classification as prebiotic at the present time. These compounds include:

Germinated barley foodstuffs (Kanauchi et al. 1998a,b,c; Kanauchi, 2003);

Oligodextrans (Olano-Martin et al. 2000);

Gluconic acid (Tsukahara et al. 2002);

Gentio-oligosaccharides (Rycroft et al. 2001);

Pectic oligosaccharides (Olano-Martin et al. 2002);

Mannan oligosaccharides (White et al. 2002);

Lactose (Szilagyi, 2002);

Glutamine and hemicellulose-rich substrate (Bamba et al. 2002);

Resistant starch and its derivatives (Silvi et al. 1999; Leemann et al. 2002; Wang et al. 2002);

Oligosaccharides from melibiose (van Laere et al. 1999);

Lactoferrin-derived peptide (Lipke et al. 2002);

N-Acetylcysteine-oligosaccharides (Chen et al. 2002);

Polydextrose (Murphy, 2001);

Sugar alcohols (Piva et al. 1996).

Prebiotic responses

With regards to the selective stimulation of specific bacteria, the questions of the dose–effect relationship and of the comparison of prebiotic effects of different compounds have caused some discussion. Regarding a dose–effect relationship, initial numbers of the bacteria that will be selectively stimulated to grow (the number before prebiotic administration) strongly determines the extent of stimulation (i.e. low if the initial number is high, but high if the initial number is low) (Roberfroid et al. 1998). A dose–effect relationship can thus be demonstrated only if the same group of volunteers having similar initial numbers of the different bacteria are used to test the different doses. Comparing the effect of prebiotics, especially with the aim to compare potency in terms of active dose, in different groups of volunteers having different initial numbers of bacteria cannot be made. In addition, the biological significance of changes in numbers of bacteria is limited if these numbers are expressed in logarithmic values. Indeed, in absolute numbers (decimal values), it is the case that even a small logarithmic increase (for example, +0·1 log10) can still represent a large increase in bacterial cell population (if the initial number is 7 or 9, such an increase corresponds to +107 and +108 respectively or 100 times greater in the latter than in the former). This can have important consequences in terms of biological activity of the microflora.

Use of prebiotics for domestic animals

Companion animals are an extremely fruitful area for prebiotic use. Indeed, recent trials have emphasised the use of prebiotics in both dried and wet foods, whereby they seek to increase indigenous levels of lactobacilli and bifidobacteria (Swanson, 2002). For example, the use of oligofructose and mannose-oligosaccharides increased faecal bifidobacteria and ileal lactobacilli in dogs (Hussein et al. 1998; Hussein, 1999). Generally, for companion animal nutritional research, prebiotic use may reduce small-intestinal bacterial overgrowth, improve colonic bacterial profile, decrease faecal putrefactive compounds, and affect faecal characteristics and nutrient digestibility. Glucose-based oligosaccharides increased bifidobacteria in canine faeces (Flickinger et al. 2000). In contrast, oligofructose as a
canine prebiotic generated only the sporadic isolation of bifidobacteria (Willard et al. 2000). The feeding of oligofructose to cats elevated lactobacilli by 164-fold, but no information was provided on the bifidogenic effect (Sparkes et al. 1998). The use of inulin and oligofructose in livestock and companion animals was reviewed recently by Flickinger et al. (2003).

Prebiotics, like probiotics, have been used in livestock applications (Morisse, 1993; Waldroup et al. 1993; Oyarzabal & Conner, 1996; Hu & Wang, 2001; Xu et al. 2002a,b; Yusrizal & Chen 2003a,b). Here, the main intentions are to reduce gastrointestinal infections, improve yield, carcass quality, reduce odour, etc.

The dietary supplementation of livestock feeds with inulin and oligofructose is a promising field of research. Increased numbers of bifidobacteria by oligofructose have been observed in pigs and quails, and it has been shown that oligofructose and, to a lesser extent, inulin reduced pathogen colonisation and contamination in poultry. In young pigs, oligofructose increased caecal and colonic epithelial cell proliferation. In pigs and rabbits, both inulin and oligofructose were shown to reduce intestinal concentrations of NH₃ (Flickinger et al. 2000). Inulin and oligofructose shift the excretion of N compounds from urine to faeces and reduce the production of putrefactive fermentation endproducts. This approach may be valid for growing–finishing pigs, being largely responsible for manure production and the environmental pollution of mainly N and minerals. The observed beneficial effects of inulin and oligofructose on pig-meat quality deserve further research attention, as meat safety and eating quality are major consumer concerns (Janssens et al. 2003). Acceptable (from both an economic and nutritional point of view) inclusion levels for inulin and/or oligofructose in piglet diets vary from 0·1 to 1 %, depending on the weaning age, diet composition and infection pressure.

Supplementing broiler diets with oligofructose improved (P<0·05) body-weight gain, feed conversion, carcass weight, carcass percentage and increased the small intestine length for female birds. Both inulin and oligofructose reduced (P<0·05) serum cholesterol and abdominal fat in broilers. Oligofructose-treated females had a denser distribution of ileal villi in the small intestine. Lactobacilli counts in the female birds were increased when the diets were supplemented with either inulin or oligofructose. Among the microflora tested, the Campylobacter count of the male birds and the Salmonella counts of the female birds were lower in the caecal contents for the prebiotic-supplemented birds (Yusrizal & Chen, 2003b).

**Future perspectives and conclusions**

Prebiotics have great potential as agents to improve or maintain a balanced intestinal microflora to enhance health and wellbeing. They can be incorporated into many food-stuffs (Table 4). There are, however, several questions that still need to be answered. For example, the present review has based its conclusions on prebiotic classification from current evidence. As this continues to accumulate, the picture will become clearer, for example in classifying certain carbohydrates where evidence is currently sparse or absent. Moreover, as better information on structure–function relationships accrues, as well as individual metabolic profiles of target bacteria, then it may be easier to tailor prebiotics into specific health attributes. Much more information is needed on the fine structure of the changes brought about by the regular intake of prebiotics. With the new generation of molecular microbiological techniques now becoming available, it will be possible to gain definitive information on the species rather than genera that are influenced by the test carbohydrate. If comparative information is to be gathered on structure–function relationships in prebiotic oligosaccharides, a rigorous approach to the evaluation of these molecules will be required. Such thorough comparative studies will allow intelligent choices when incorporating prebiotics into functional foods and should increase confidence amongst consumers and regulatory authorities. Similarly, it may be possible to incorporate further biological functionality into the concept; for example, an increase in beneficial bacteria while suppressing pathogens at the same time, perhaps through anti-adhesive approaches (Gibson, 2000).

The current most popular targets for prebiotic use are lactobacilli and bifidobacteria. This is based largely upon their success in the probiotic area (Fuller, 1997; Hamburger, 1997; Majamaa, 1997; Roberfroid, 1998; Gibson, 2000; Kazuhiro Hirayama, 2000; Capurso, 2001; Fooks & Gibson, 2002; Tannock, 2002). However, as our knowledge of the gut flora diversity improves (through using the molecular procedures described earlier: p. 261), then it may...
become apparent that other micro-organisms should be fortified through their use. One example may be the eubacteria that produce butyric acid, a metabolite seen as beneficial for gut functionality and potentially protective against bowel cancer (Antalis, 1995; D’Argenio, 1996).

The concept currently targets microbial changes at the genus level. Future developments may elucidate molecules that induce species-level effects. This is because certain species of bifidobacteria and lactobacilli may be more desirable than others. It is important for colonic function to identify molecules that can be fermented distally, the principal site of chronic gut disorders such as bowel cancer and ulcerative colitis.

At the end of the present review aimed at updating the prebiotic definition, it must be underlined that only three carbohydrates, essentially non-digestible oligosaccharides, today fulfil the criteria for prebiotic classification (Table 5). For the other candidates, data are promising but more studies are still required. In particular, it must be stressed that data to fulfil criterion 1, i.e. ‘resistance to gastric acidity, hydrolysis by mammalian enzymes and gastrointestinal absorption’, are lacking. Similarly (more) in vitro data in mixed culture systems and (more) in vivo data, especially, in reliable human nutrition intervention studies, are required.

The original definition of a prebiotic considers only microbial changes in the colonic ecosystem of man. However, it may be timely to extrapolate this into other areas that may benefit from a selective targeting of particular micro-organisms. As such, we propose a refining of the original definition to:
‘A prebiotic is a selectively fermented ingredient that allows specific changes, both in the composition and/or activity in the gastrointestinal microflora that confers benefits upon host wellbeing and health.’

The real drive is the nutritional, physiological and microbial benefits of prebiotics that have been published so far (Table 6) and their future exploitation in authentic health issues.

### Table 5. Summary and conclusion on the prebiotic effect of various oligosaccharides

<table>
<thead>
<tr>
<th>Carbohydrate</th>
<th>Non-digestibility</th>
<th>Fermentation</th>
<th>Selectivity</th>
<th>Prebiotic status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inulin</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Transgalacto-oligosaccharides</td>
<td>Probable</td>
<td>?</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Lactulose</td>
<td>Probable</td>
<td>?</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Isomalto-oligosaccharides</td>
<td>Partly</td>
<td>Yes</td>
<td>Promising</td>
<td>No</td>
</tr>
<tr>
<td>Lactosucrose</td>
<td>NA</td>
<td>NA</td>
<td>Promising</td>
<td>No</td>
</tr>
<tr>
<td>Xylo-oligosaccharides</td>
<td>NA</td>
<td>NA</td>
<td>Promising</td>
<td>No</td>
</tr>
<tr>
<td>Soyabean oligosaccharides</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>No</td>
</tr>
<tr>
<td>Gluco-oligosaccharides</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>No</td>
</tr>
</tbody>
</table>

?, Preliminary data, but further research still needed; NA, data not available.

### Table 6. Reported nutritional and physiological effects and health outcomes associated with prebiotic intake both in experimental animals and in human subjects

<table>
<thead>
<tr>
<th>Health aspect</th>
<th>Summary of the effect</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bowel cancer</td>
<td>Positive effects on biomarkers of colonic cancer through probiotic, prebiotic and symbiotic use</td>
<td>Rafter (2002)</td>
</tr>
<tr>
<td></td>
<td>Reduction in aberrant crypt foci with inulin + Lactobacillus acidophilus</td>
<td>Bolognani et al. (2001)</td>
</tr>
<tr>
<td></td>
<td>Both probiotics and prebiotics are protective</td>
<td>Wollowski et al. (2001)</td>
</tr>
<tr>
<td></td>
<td>Positive effects with both inulin + Lactobacillus acidophilus in apoptosis stimulation, using the rat colon</td>
<td>Hughes &amp; Rowland (2001)</td>
</tr>
<tr>
<td></td>
<td>Symbiotics are effective at tumour suppression</td>
<td>Burns &amp; Rowland (2000)</td>
</tr>
<tr>
<td></td>
<td>Both probiotics and prebiotics exert inhibitory effects on aberrant crypt foci in animal models</td>
<td>Brady et al. (2000)</td>
</tr>
<tr>
<td></td>
<td>Inulin as a prebiotic was effective</td>
<td>Gallaher &amp; Khl (1999)</td>
</tr>
<tr>
<td></td>
<td>Inulin can exert several positive effects</td>
<td>Pool-Zobel et al. (2002)</td>
</tr>
<tr>
<td></td>
<td>Positive effects with symbiotic use (Bifidobacterium longum, inulin) on NH3, colonic lesions, genotoxic enzymes</td>
<td>Rowland et al. (1998)</td>
</tr>
<tr>
<td></td>
<td>In rats treated with carcinogens, inulin with bifidobacteria repressed effects but this did not occur with soya or wheat</td>
<td>Gallaher &amp; Khl (1999)</td>
</tr>
<tr>
<td></td>
<td>Dietary inulin reduced aberrant crypt foci incidence in the colon in rats, caecal weight was increased and caecal pH decreased</td>
<td>Vergheese et al. (2002)</td>
</tr>
<tr>
<td></td>
<td>Addition of oligofructose to a standard diet reduced the number of experimentally induced breast tumours in female rats</td>
<td>Taper &amp; Roberfroid (1999)</td>
</tr>
<tr>
<td></td>
<td>Oligofructose reduced the incidence of colon tumours and concomitantly developed gut-associated lymphoid tissue in Min mice</td>
<td>Pierre et al. (1997)</td>
</tr>
<tr>
<td></td>
<td>Growth of mouse tumours was significantly inhibited by supplementation of the diet with either inulin or oligofructose</td>
<td>Taper et al. (1998)</td>
</tr>
<tr>
<td></td>
<td>Aberrant crypt foci were significantly inhibited by inulin and oligofructose feeding</td>
<td>Reddy et al. (1997)</td>
</tr>
<tr>
<td></td>
<td>Aberrant crypt multiplicity incidence in rats fed galacto-oligosaccharides was reduced</td>
<td>Wijnands et al. (2001)</td>
</tr>
<tr>
<td></td>
<td>Prebiotic administration in the diet inhibited carcinogenesis in rats</td>
<td>Femia et al. (2002)</td>
</tr>
<tr>
<td>Inflammatory bowel disease</td>
<td>Lactulose reduced symptoms in patients with inflammatory bowel disease but the duration was too short (3 weeks) to generate significance</td>
<td>Szilagyi et al. (2002)</td>
</tr>
<tr>
<td></td>
<td>Summarises promising trials with probiotics and prebiotics</td>
<td>Katz (2002)</td>
</tr>
</tbody>
</table>

Continued
### Table 6. Continued

<table>
<thead>
<tr>
<th>Health aspect</th>
<th>Summary of the effect</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pathogenic agents</td>
<td>Oligofructose and inulin protected against <em>Listeria monocytogenes</em> and <em>Salmonella typhimurium</em> as well as chemically induced tumours  &lt;br&gt; Reduced incidence of travellers’ diarrhoea with inulin  &lt;br&gt; Inulin affects immunology through macrophage activation and through cell-wall fragments of bifidobacteria  &lt;br&gt; Inulin in an oral electrolyte solution accelerated beneficial bacteria and recovery from diarrhoea  &lt;br&gt; Prebiotic fermentation increased organic acids which may be useful for suppressing pathogens  &lt;br&gt; <em>Bifidobacterium breve</em> plus transgalactosylated oligosaccharides inhibited <em>Salmonella enteritica</em></td>
<td>Buddington et al. (2002)  &lt;br&gt; Cummings et al.  &lt;br&gt; Meyer et al. (2000)  &lt;br&gt; Oli et al. (1998)  &lt;br&gt; Kleeosen et al. (1997a)  &lt;br&gt; Asahara et al. (2001)</td>
</tr>
<tr>
<td>CHD</td>
<td>Inulin decreased triacylglycerols, trend towards decreased cholesterol also  &lt;br&gt; Inulin + lactobacilli decreased serum total cholesterol, and also LDL-cholesterol and the LDL:HDL ratio  &lt;br&gt; Oligofructose supplementation resulted in a decrease in postprandial triacylglycerolaemia and protected rats against an increase in non-esterified cholesterol serum level induced by a high-fat diet  &lt;br&gt; Chronic feeding of rats with oligofructose significantly reduced the capacity of isolated hepatocytes to synthesise triacylglycerols  &lt;br&gt; Triacylglycerol and phospholipid concentrations in the liver and blood were decreased with oligofructose  &lt;br&gt; Addition of oligofructose prevented some lipid disorders, lowered fatty acid synthase activity in the liver of rats</td>
<td>Brightenti et al. (1997)  &lt;br&gt; Schaafsma et al. (1998)  &lt;br&gt; Kok et al. (1998)  &lt;br&gt; Fioaliso et al. (1995)  &lt;br&gt; Kok et al. (1996)  &lt;br&gt; Agheli et al. (1998)</td>
</tr>
<tr>
<td>Necrotising enterocolitis</td>
<td>Oligofructose enhanced the bifidogenic effect, decreased severity and necrotising enterocolitis lesions in a quail model  &lt;br&gt; Gnotobiotic quails as a model showed that oligofructose could act as an anti-infective agent and decrease the occurrence and severity of lesions in necrotising enterocolitis  &lt;br&gt; Dietary inulin improves distal colitis induced by dextran sodium sulfate in the rat</td>
<td>Catala et al. (1999)  &lt;br&gt; Butel et al. (2002)  &lt;br&gt; Videla et al. (2001)</td>
</tr>
<tr>
<td>Mineral availability</td>
<td>Prebiotics have good possibilities for osteoporosis protection  &lt;br&gt; An inulin–oligosaccharide mixture generated increased Ca absorption from orange juice  &lt;br&gt; Oligofructose improved Mg absorption in post-menopausal women  &lt;br&gt; An increase in true fractional Ca absorption was seen after ingestion of oligofructose  &lt;br&gt; Ovariectomy-induced loss of bone structure in theibia of rats was prevented by oligofructose  &lt;br&gt; Mg and Ca absorption were raised significantly by oligofructose feeding  &lt;br&gt; Feeding inulin decreased faecal excretion of Ca, Mg, Fe, Zn and Cu  &lt;br&gt; Beagle dogs fed inulin had a higher capacity for carrier-mediated glucose uptake than dogs fed cellulose  &lt;br&gt; Lactulose stimulated Ca absorption in rats</td>
<td>Cashman (2002)  &lt;br&gt; Griffin et al. (2002)  &lt;br&gt; Tahiri et al. (2001)  &lt;br&gt; van der Heuvel et al. (1999)  &lt;br&gt; Scholz-Ahrens et al. (2002)  &lt;br&gt; Beynen et al. (2002)  &lt;br&gt; Delzenne et al. (1995)  &lt;br&gt; Buddingh et al. (1999)  &lt;br&gt; Brommage et al. (1993)</td>
</tr>
<tr>
<td>Obesity</td>
<td>Oligofructose could counteract both the fat mass development and the hepatic steatosis that occurs in obese Zucker rats</td>
<td>Daubioul et al. (2000)</td>
</tr>
</tbody>
</table>

References


Levrat MA, Rémésy C & Demigné C (1991) High propionic-acid
Kleessen B, Sykura B, Zunft HJ & Blaut M (1997
Katz JA (2002) Advances in the medical therapy of inflammatory
Knol J (2001) Stimulation of endogenous bifidobacteria in term
Kumemura M, Hashimoto F, Fujii C, Matsuo K, Kimura H,


